---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-009306"
form_type: "8-K"
ticker: "EMED"
cik: "0001715819"
company_name: "Electromedical Technologies, Inc"
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T03:56:53.100319+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CEO Matthew Wolfson granted voting control via Series B preferred; authorized shares increased to 2B+

## Summary
- Employment agreement gives Wolfson one Series B preferred share with voting control equal to all common shares plus 100k votes on fully diluted basis.
- Wolfson retains $265k/yr CEO salary plus $100k/yr CFO salary; incentives include up to 25M common shares for annual growth and cash bonuses for quarterly growth.
- Robert L. Hymers III appointed as independent director and compensation committee member for 6-month term; receives $5k monthly in common shares.
- Charter amendment increases authorized capital to 2,000,000,001 shares (199M common, 1M Series A preferred, 1 Series B preferred); filed with Delaware.

## SEC filing metadata
- accession: 0001104659-23-009306
- form_type: 8-K
- ticker: EMED
- cik: 0001715819
- company_name: Electromedical Technologies, Inc
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.03, 5.01, 5.02, 5.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/tm235211d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-009306
- JSON: https://secwatch.observer/filing/0001104659-23-009306.json
- Plain text: https://secwatch.observer/filing/0001104659-23-009306.txt

## Key facts
- Executive change
  Robert L. Hymers III was appointed as Independent Director at Electromedical Technologies, Inc.
  - Action: appointed
  - Role: Independent Director
  source text: On February 1, 2023, effective January 1, 2023, the Company appointed Robert L. Hymers, III, age 39, as an independent director and member of the compensation committee of the Company for a term of six months.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm
- Governance Changes
  Electromedical Technologies, Inc: Increased authorized shares to two billion and one, including Common Stock, Series A Preferred, and Series B Preferred; par value $0.00001 per share (effective 2023-01-31).
  - Change: charter amendment
  - Effective: 2023-01-31
  source text: On January 31, 2023, the board of directors approved a resolution to amend the Company’s Certificate of Incorporation to: (1) increase the Company’s authorized shares to two billion and one shares of capital stock, including: one hundred and ninety-nine million shares designated as “Common Stock,” with a par value of $0.00001 per share; one million shares designated as “Series A Preferred Shares,” par value $0.00001 per share; and one share designated as “Series B Preferred Shares,” par value $0.00001 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm
- M&A Transactions
  Electromedical Technologies, Inc underwent a change of control involving Matthew Wolfson (closed 2023-01-26).
  - Action: change of control
  - Counterparty: Matthew Wolfson
  - Closing: 2023-01-26
  source text: Matthew Wolfson entered into an executive employment agreement. The Company agreed, as partial consideration
  evidence_url: https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.